A detailed history of Bank Of America Corp transactions in Altimmune, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 149,507 shares of ALT stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
149,507
Previous 279,338 46.48%
Holding current value
$1.23 Million
Previous $1.86 Million 50.62%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$5.5 - $8.1 $714,070 - $1.05 Million
-129,831 Reduced 46.48%
149,507 $917,000
Q2 2024

Aug 14, 2024

SELL
$5.91 - $10.23 $1.3 Million - $2.26 Million
-220,534 Reduced 44.12%
279,338 $1.86 Million
Q1 2024

May 15, 2024

BUY
$8.22 - $13.81 $3.89 Million - $6.53 Million
472,895 Added 1752.96%
499,872 $5.09 Million
Q4 2023

Feb 14, 2024

SELL
$2.14 - $11.62 $117,049 - $635,567
-54,696 Reduced 66.97%
26,977 $303,000
Q2 2023

Aug 14, 2023

SELL
$3.45 - $5.97 $1.95 Million - $3.37 Million
-564,473 Reduced 87.36%
81,673 $288,000
Q1 2023

May 12, 2023

BUY
$4.19 - $16.83 $488,176 - $1.96 Million
116,510 Added 22.0%
646,146 $2.73 Million
Q4 2022

Feb 10, 2023

BUY
$8.74 - $16.45 $2.34 Million - $4.4 Million
267,432 Added 101.99%
529,636 $8.71 Million
Q3 2022

Nov 14, 2022

BUY
$10.67 - $22.41 $2.1 Million - $4.42 Million
197,231 Added 303.56%
262,204 $3.35 Million
Q2 2022

Aug 12, 2022

BUY
$3.94 - $11.77 $166,011 - $495,928
42,135 Added 184.5%
64,973 $760,000
Q1 2022

May 16, 2022

SELL
$5.9 - $9.45 $1.2 Million - $1.92 Million
-202,732 Reduced 89.88%
22,838 $140,000
Q4 2021

Feb 08, 2022

BUY
$8.69 - $12.48 $1.77 Million - $2.55 Million
204,148 Added 952.98%
225,570 $2.07 Million
Q3 2021

Nov 15, 2021

BUY
$8.43 - $16.81 $25,500 - $50,850
3,025 Added 16.44%
21,422 $243,000
Q2 2021

Sep 13, 2021

BUY
$9.85 - $16.46 $181,210 - $302,814
18,397 New
18,397 $181,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $404M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.